Fluoxetine updated on 07-01-2025

Microcephaly / Small head circumference for gestational age

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10599
R39112		 Kerr, 2018 Isolated microcephaly (ICD-9 - Within 6 months after delivery) 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 0.83 [0.05;13.59] C 0/126   57/11,990 57 126
ref
S7693
R22810		 Kivistö, 2016 Head circumference <10th centile (in newborns) during pregnancy (anytime or not specified) retrospective cohort unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.70 [0.66;4.40] -/-   1,709/- - -
ref
S15005
R61442		 Chambers, 1996 Microcephalic (<3rd percentile) 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 2.23 [0.31;16.04] C 2/95   2/209 4 95
ref
Total 3 studies 1.67 [0.74;3.79] 61 221
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kerr, 2018Kerr, 2018 0.83[0.05; 13.59]571269%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Kivistö, 2016Kivistö, 2016 1.70[0.66; 4.40]--74%ROB confusion: seriousROB selection: criticalROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Chambers, 1996Chambers, 1996 2.23[0.31; 16.04]49517%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: criticalROB reporting: moderate Total (3 studies) I2 = 0% 1.67[0.74; 3.79]612210.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.79[0.76; 4.20]4950%NAKivistö, 2016 Chambers, 1996 2 case control studiescase control studies 0.83[0.05; 13.59]57126 -NAKerr, 2018 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.67[0.74; 3.79]612210%NAKerr, 2018 Kivistö, 2016 Chambers, 1996 3 Tags Adjustment   - No  - No 1.60[0.32; 8.04]612210%NAKerr, 2018 Chambers, 1996 2   - Yes  - Yes 1.70[0.66; 4.39]-- -NAKivistö, 2016 1 Monotherapy   - no or not specified  - no or not specified 1.60[0.32; 8.04]612210%NAKerr, 2018 Chambers, 1996 2   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.70[0.66; 4.39]-- -NAKivistö, 2016 1 All studiesAll studies 1.67[0.74; 3.79]612210%NAKerr, 2018 Kivistö, 2016 Chambers, 1996 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.67[0.74; 3.79]1,7612210%NAKerr, 2018 Kivistö, 2016 Chambers, 1996 30.510.01.0